ROCKVILLE, Md.--(BUSINESS WIRE)--Micromet, Inc. (Nasdaq: MITI) today announced that data from a Phase 2 clinical trial of the Company's lead product candidate blinatumomab in patients with minimal residual disease positive (MRD) acute lymphoblastic leukemia (ALL) were published in the May 16th on-line edition of the Journal of Clinical Oncology (JCO). Results of the study demonstrated that blinatumomab produced durable remissions in front-line adult ALL patients at high risk of relapse. Blinatumomab is the most advanced of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.
